Lignes directrices de pratique clinique 2008 de l - Canadian ...

S198 | LiGnes directrices de pratique cLinique 2008
69. Wyatt JW, Frias JL, Hoyme HE, et al; IONS study group. Congenital
anomaly rate in offspring of mothers with diabetes treated with
insulin lispro during pregnancy. Diabet Med. 2005;22:803-807.
70. Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart Pregnancy
Study Group. Maternal glycemic control and hypoglycemia in
type 1 diabetic pregnancy: a randomized trial of insulin aspart
versus human insulin in 322 pregnant women. Diabetes Care.
2007;30:771-776.
71. Mecacci F, Carignani L, Cioni R, et al. Maternal metabolic control
and perinatal outcome in women with diabète gestationnel treated
with regular or lispro insulin: comparison with non-diabetic pregnant
women. Eur J Obstet Gynecol Reprod Biol. 2003;111:19-24.
72. Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an
insulin analog, insulin aspart, and regular human insulin with
no insulin in diabète gestationnel mellitus. Diabetes Care.
2003;26:183-186.
73. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and
meta-analysis of short-acting insulin analogues in patients with
diabetes mellitus. Arch Intern Med. 2005;165:1337-1344.
74. Gallen IW, Jaap A, Roland JM, Chirayath HH. Survey of glargine
use in 115 pregnant women with type 1 diabetes. Diabet Med.
2008;25:165-169.
75. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor
binding and metabolic and mitogenic potencies of insulin analogs
designed for clinical use. Diabetes. 2000;49:999-1005.
76. Gutzin SJ, Kozer E, Magee LA, et al. The safety of oral hypoglycemic
agents in the first trimester of pregnancy: a meta-analysis.
Can J Clin Pharmacol. 2003;10:179-183.
77. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic
agents in 118 diabetic pregnancies. Diabet Med. 2000;17:
507-511.
78. Ekpebegh CO, Coetzee EJ, van der Merwe L, et al. A 10-year retrospective
analysis of pregnancy outcome in pregestational type 2
diabetes: comparison of insulin and oral glucose-lowering agents.
Diabet Med. 2007;24:253-258.
79. Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy
throughout pregnancy reduces the development of diabète gestationnel
in women with polycystic ovary syndrome. Fertil Steril.
2002;77:520-525.
80. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and
motor-social development during the first 18 months of life in
126 infants born to 109 mothers with polycystic ovary syndrome
who conceived on and continued metformin through pregnancy.
Hum Reprod. 2004;19:1323-1330.
81. Glueck CJ, Salehi M, Sieve L, et al. Growth, motor, and social
development in breast- and formula-fed infants of metformintreated
women with polycystic ovary syndrome. J Pediatr. 2006;
148:628-632.
82. Mayer-Davis EJ, Rifas-Shiman SL, Zhou L, et al. Breast-feeding
and risk for childhood obesity: does maternal diabetes or obesity
status matter? Diabetes Care. 2006;29:2231-2237.
83. Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of met-
formin into human milk. Clin Pharmacol Ther. 2003;73:71-77.
84. Briggs GG, Ambrose PJ, Nageotte MP, et al. Excretion of metformin
into breast milk and the effect on nursing infants. Obstet
Gynecol. 2005;105:1437-1441.
85. Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin
into human milk. Diabetologia. 2002;45:1509-1514.
86. Feig DS, Briggs GG, Kraemer JM, et al. Transfer of glyburide and
glipizide into breast milk. Diabetes Care. 2005;28:1851-1855.
87. Umpierrez GE, Latif KA, Murphy MB, et al. Thyroid dysfunction
in patients with type 1 diabetes: a longitudinal study. Diabetes
Care. 2003;26:1181-1185.
88. Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of
diabetes. Glycemic control prevents congenital anomalies. JAMA.
1991;265:731-736.
89. McElvy SS, Miodovnik M, Rosenn B, et al. A focused preconceptional
and early pregnancy program in women with type 1
diabetes reduces perinatal mortality and malformation rates to
general population levels. J Matern Fetal Med. 2000;9:14-20.
90. Jovanovic L, Knopp RH, Kim H, et al. Elevated pregnancy losses
at high and low extremes of maternal glucose in early normal
and diabetic pregnancy: evidence for a protective adaptation in
diabetes. Diabetes Care. 2005;28:1113-1117.
91. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during
early pregnancy and fetal malformations in women with type I
diabetes mellitus. Diabetologia. 2000;43:79-82.
92. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration
to estimate the risk of congenital anomalies in the offspring
of women with pre-pregnancy diabetes. Diabetes Care. 2007;
30:1920-1925.
93. Hiilesmaa V, Suhonen L, Teramo K. Glycaemic control is associated
with pre-eclampsia but not with pregnancy-induced hypertension
in women with type I diabetes mellitus. Diabetologia.
2000;43:1534-1539.
94. Hsu CD, Tan HY, Hong SF, et al. Strategies for reducing the frequency
of preeclampsia in pregnancies with insulin-dependent
diabetes mellitus. Am J Perinatol. 1996;13:265-268.
95. Edison RJ, Muenke M. Central nervous system and limb anomalies
in case reports of first-trimester statin exposure. N Engl J Med.
2004;350:1579-1582.
96. The Diabetes Control and Complications Trial Research Group.
Early worsening of diabetic retinopathy in the Diabetes Control
and Complications Trial. Arch Ophthalmol. 1998;116:874-886.
97. Rizzo T, Metzger BE, Burns WJ, et al. Correlations between
antepartum maternal metabolism and child intelligence. N Engl J
Med. 1991;325:911-916.
98. Metzger BE, Coustan DR. Summary and recommendations of the
Fourth International Workshop – Conference on Diabète gestationnel
Mellitus. Diabetes Care. 1998;21(Suppl 2):B161-B167.
99. Dyck R, Klomp H, Tan LK, et al. A comparison of rates, risk
factors, and outcomes of diabète gestationnel between aboriginal
and non-aboriginal women in the Saskatoon Health District.
Diabetes Care. 2002;25:487-493.